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Human African trypanosomiasis (HAT), a lethal disease induced by Trypanosoma brucei
gambiense, has a range of clinical outcomes in its human host in West Africa: an acute form
progressing rapidly to second stage, spontaneous self-cure and individuals able to regulate
parasitaemia at very low levels, have all been reported from endemic foci. In order to test if
this clinical diversity is influenced by host genetic determinants, the association between
candidate gene polymorphisms and HAT outcome was investigated in populations from
HAT active foci in Guinea.
Methodology and results
Samples were collected from 425 individuals; comprising of 232 HAT cases, 79 subjects
with long lasting positive and specific serology but negative parasitology and 114 endemic
controls. Genotypes of 28 SNPs in eight genes passed quality control and were used for an
association analysis. IL6 rs1818879 allele A (p = 0.0001, OR = 0.39, CI95 = [0.24–0.63],
BONF = 0.0034) was associated with a lower risk of progressing from latent infection to
active disease. MIF rs36086171 allele G seemed to be associated with an increased risk
(p = 0.0239, OR = 1.65, CI95 = [1.07–2.53], BONF = 0.6697) but did not remain significant
after Bonferroni correction. Similarly MIF rs12483859 C allele seems be associated with
latent infections (p = 0.0077, OR = 1.86, CI95 = [1.18–2.95], BONF = 0.2157). We confirmed
earlier observations that APOL1 G2 allele (DEL) (p = 0.0011, OR = 2.70, CI95 = [1.49–4.91],
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BONF = 0.0301) is associated with a higher risk and APOL1 G1 polymorphism (p = 0.0005,
OR = 0.45, CI95 = [0.29–0.70], BONF = 0.0129) with a lower risk of developing HAT. No
associations were found with other candidate genes.
Conclusion
Our data show that host genes are involved in modulating Trypanosoma brucei gambiense
infection outcome in infected individuals from Guinea with IL6 rs1818879 being associated
with a lower risk of progressing to active HAT. These results enhance our understanding of
host-parasite interactions and, ultimately, may lead to the development of new control tools.
Author summary
Human African Trypanosomiasis (HAT) known as sleeping sickness is a lethal neglected
disease in West and Central Africa, caused by the parasite Trypanosoma brucei gambiense
that is transmitted by tsetse flies Glossina palpalis gambiensis. The disease has long been
considered to be invariably fatal, but field studies show that T. b. gambiense infection leads
to a wide diversity of clinical outcomes. An acute form progressing rapidly to second
stage; spontaneous self-cure and individuals able to control parasitaemia at very low levels
(latent infections). In the present study, we test for associations between candidate gene
polymorphisms and different HAT phenotypes (HAT confirmed cases, latent infections)
and endemic controls, in order to identify relationships between the clinical diversity and
host genetic determinants. Our results, based on clinical, serological and parasitological
observations, combined with genotypes and association analysis form the most complete
study of host genetic determinants and clinical diversity of HAT in Guinea to date. We
show that host genes are involved in modulating responses in Trypanosoma brucei gam-
biense infected individuals. A new association was found between IL6 rs1818879 and a
reduced risk of progressing from latent infection to active HAT. These results constitute
an important stage toward the identification of the natural human mechanisms involved
in T. b. gambiense infection regulation.
Introduction
Human African trypanosomiasis (HAT) known as sleeping sickness is a neglected disease of
sub-Saharan Africa caused by two sub-species of trypanosomes, Trypanosoma brucei (T. b.)
gambiense (in West and Central Africa) and T. b. rhodesiense (in East and South Africa), with
T. b. gambiense causing > 95% of all cases [1]. In West Africa, Guinea is the country with the
highest prevalence for HAT, especially on the coast [2], where the vector, the tsetse fly Glossina
palpalis gambiensis is abundant [3]. In the active foci of Boffa, Dubreka and Forecariah preva-
lence in humans is generally around 0.5–1%, but can go up to 5% in some villages [1,3,4].
HAT caused by T. b. gambiense is classically described as a chronic disease with an early hae-
molymphatic phase (first stage) associated with nonspecific symptoms such as intermittent
fevers and headaches, followed by a meningoencephalitic phase (second stage) where the para-
site invades the central nervous system (CNS) leading to neurological disorders. In the absence
of treatment, HAT is widely assumed to be 100% fatal. However, asymptomatic carriers and
spontaneous cure without treatment have been described in old [5] and more recent reports
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[6], strengthening the evidence for human trypanotolerance / resistance [7–10]. Indeed, a
recent long-term longitudinal survey in Coˆte d’Ivoire found people who were initially diag-
nosed by microscopy but on follow-up examination, up to 15 years later, had no detectable
parasitaemia by microscopy, despite not having received treatment [6]. A drop in antibody
titers to seronegative levels was detected in some of these subjects, indicating that they have
self-cured. In contrast, others maintained a long-lasting serological response, being Card
Agglutination Test for Trypanosomiasis (CATT) and trypanolysis (TL) test positive but had
no parasites detectable by microscopy, suggesting that these individuals were able to control
blood parasitaemia at very low levels and were considered as asymptomatic carriers of para-
sites and were classified as latent infections [4,9,11].
Many factors could play a role in this variability of response to infection, and the respective
roles of the virulence of the parasite and host susceptibility in this clinical diversity remain
unclear [12]. It has been suggested that genetic polymorphism of the parasite could be associ-
ated with asymptomatic and very chronic infections [11]. Nevertheless, host genetic factors
involved in the control of immunity could regulate infection levels or mortality rates, as has
been shown for Trypanosoma congolense infections in experimental models [13,14] and also T.
brucei spp in humans [15–20].
Hence, the purpose of the present study was to study the role of single nucleotide polymor-
phisms (SNPs) in IL4, IL6, IL8, IL10, IFNG, APOL1, TNFA, HPR, HLA-G, HLA-A, HP, and
MIF genes on susceptibility/resistance to HAT by means of an association study between HAT
cases, seropositive microscopically aparasitaemic subjects with latent infections, and controls
in order to explore their possible role in human immunity to this complex disease.
Methods
Informed consent and ethics statement
The study was performed as part of medical survey conducted by the national control program
according to the national HAT diagnostic procedures and was approved by the Ministry of
Health in Guinea. All participants were informed about the objective of the study in their own
language and signed an informed consent form. For participants under 18 year of age, a writ-
ten informed consent was obtained from the parent. This study is part of a TrypanoGEN proj-
ect which aims to understand the genetic basis of human susceptibility to trypanosomiasis and
samples were archived in the TrypanoGEN Biobank at CIRDES [21] for which approval was
obtained from the Guinea National ethics committee (1-22/04/2013).
Study population
The study was carried out in three active HAT foci (Dubreka, Boffa, and Forecariah) in the
mangrove areas of coastal Guinea. Most of the population is from the Soussou ethnic group
and lives in small villages scattered along mangrove channels [1,3]. All subjects included in
this study were identified during medical monitoring surveys organized by the National HAT
Control Program (NCP) between November 2007 and December 2013, according to the
WHO and NCP policies described elsewhere [4]. Blood (5 ml) was collected in heparinized
tubes. For individuals who are positive to the CATT (Card Agglutination Test for Trypanoso-
miasis) serological mass screening test, a twofold plasma dilution series was tested to deter-
mine their CATT end titer. All individuals with titers of 1/4 or greater were submitted to
microscopic examination of lymph node aspirates whenever swollen lymph nodes were pres-
ent; 350 ml of buffy coat was then examined by using the mini-anion exchange column
(mAECT) test which has shown to have a threshold of detection of 10 trypanosomes ml-1 of
blood [3,22]. Samples that were CATT negative, CATT positive with lymph node and/or buffy
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coat negative for trypanosomes were all subject to the immune trypanolysis test (TL), which is
a serological test that is highly specific for T. b. gambiense [23]. 425 individuals were selected
according to the study inclusion criteria below.
Phenotype definitions
Samples were classified into three phenotypes: (1) Cases or active HAT patients are defined as
subjects presenting as positive on both serological tests (CATT and TL) and parasitological
tests (mAECT and/or examination of cervical lymph juice aspirates); (2) latent infections have
CATT plasma dilution end titer 1/4 or higher; TL positive and are parasitology negative and
maintain this phenotype for at least two years; (3) endemic controls who have serology (CATT
and TL) negative and living in the same village as a HAT patient and/or a seropositive subject.
All individuals live in the same area and had been exposed to the risk of infection since birth
[21].
Study design
This study was one of six studies of populations of HAT endemic areas in DRC, Cameroon,
Cote d’Ivoire, Guinea, Malawi and Uganda. The studies were designed to have 80% power to
detect odds ratios (OR) >2 for loci with disease allele frequencies of 0.15–0.65 with the 80
SNPs genotyped. The study design included a total of 425 samples: 232 HAT cases, 79 seropos-
itive and 114 uninfected or endemic controls. Power calculations were undertaken using the
genetics analysis package gap in r [24].
DNA extraction
DNA was extracted from buffy coat (BC) samples using the Qiagen DNA extraction kit
(QIAamp DNA Blood Midi Kit) following the instructions of the manufacturer. The DNA
extract was stored at -20˚C. After extraction each DNA sample was quantified on a spectro-
photometer (NanoDrop).
Single Nucleotide Polymorphisms (SNPs) selection
80 SNP were selected for genotyping using two strategies: 1) specific SNP in IL10, TNFA,
HLA-A, HLA-G, APOL1, MIF, HPR and HP had been previously reported to be associated with
HAT or 2) IL4, IL8, IL6, HLA-G and IFNG were scanned for sets of linked marker SNP (r2 <
0.5) across each gene. The SNPs in this second group of genes were selected using a merged set
of SNP obtained from low fold coverage (8-10x) whole genome shotgun data generated from
230 residents living in regions (Democratic Republic of Congo, Guinea Conakry, Ivory Coast
and Uganda) where trypanosomiasis is endemic (TrypanoGEN consortium, European Nucle-
otide Archive Study Number EGAS00001002482) and 1000 Genomes Project data from Afri-
can populations, only published SNP with dbSNP identifiers were used in the design. Linkage
(r2) between loci was estimated using Plink and sets of SNP that covered the gene were identi-
fied. Some SNP loci were excluded during assay development or failed to genotype and were
not replaced.
Genotyping
Samples were submitted to Plateforme Genome Transcriptome de Bordeaux at INRA Site de
Pierroton. Multiplex design (two sets of 40 SNPs) was performed using Assay Design Suite
v2.0 (Agena Biosciences). SNP genotyping was achieved with the iPLEX Gold genotyping kit
(Agena Biosciences) for the MassArray iPLEX genotyping assay, following the manufacturer’s
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instructions. Products were detected on a MassArray mass spectrophotometer and data were
acquired in real time with MassArray RT software (Agena Biosciences). SNP clustering and
validation was carried out with Typer 4.0 software (Agena Biosciences). APOL1 rs71785313
SNP was genotyped again by LGC Genomics, Hoddesden, United Kingdom, using the PCR
based KASP assay [25].
Statistical analysis
Plink v1.9 [26] was used for statistical analysis, allele frequencies were analyzed by simple allele
counting and the R 3.3.1 software package was used for data visualization (R Foundation for
Statistical Computing, Vienna Austria). For quality control and filtering, SNPs loci with miss-
ing genotypes > 10% and individuals with missing loci > 10% were removed. In addition
SNPs with Hardy equilibrium (HWE) p< 0.001, minor allele frequency MAF < 0.05, SNPs in
linkage with adjacent SNPs (r2 > 0.5) and monomorphic loci were also pruned [27]. 28 SNPs
were remaining after filtering and LD pruning and were used to test association with the dis-
ease. Association analysis’s were done using pairwise comparison between cases-controls,
cases-latent infections and latent infections-controls. The Fisher exact test was used to test for
significant differences in allele frequencies between phenotypes. We also tested for association
with disease under additive model allowing for non-genetic risk factors “sex and age”. Odds
ratio for the minor allele A1, and p-value for association, were adjusted for age and sex. In all
analysis, results were adjusted by Bonferroni correction for multiple comparisons. The Bonfer-
roni correction establishes the threshold of significance at α/n. P-values smaller than 0.05/
28 = 0.0018 or an adjusted p-value <0.05 were considered significant.
Results
Genes and SNPs selected
In total 12 candidate genes that have known or plausible associations with HAT were identi-
fied from the literature. 80 SNPs were identified 17 in HLA-G, 2 in HLA-A, 2 in HPR, 10 in
IFNG, 16 in IL4, 12 in IL6, 6 in IL8, 1 in IL10, 8 in MIF, 3 in TNFA, 1 in HP and 2 in APOL1. 28
of these 80 SNPs remained after quality control and linkage pruning and were used for associa-
tion analysis (Table 1). These SNPs are in HWE, MAF > 5% and LD r2 < 0.5. SNPs with allele
Table 1. SNPs remaining after quality control and LD pruning.
CHR Genes SNPs selected SNPs pass filtered
1 IL10 1 0
4 IL8 6 4
5 IL4 16 3
6 HLAG 17 2
6 TNFA 3 2
6 HLAA 2 0
7 IL6 12 6
12 IFNG 10 5
16 HPR 2 0
16 HP 1 1
22 MIF 8 3
22 APOL1 2 2
Total 12 80 28
CHR: Chromosome number, SNP: single nucleotide polymorphism
https://doi.org/10.1371/journal.pntd.0005833.t001
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frequencies that deviated from HWE were removed. The allelic and minor allele carrier fre-
quencies are shown in Tables 2–4, along with the results of the association test.
Association study
The APOL1 rs73885319 polymorphism is one part of a two SNP haplotype, with derived alleles
designated “G1” composed of two tightly linked coding variants rs73885319 (S342G) and
rs60910145 (I384M) non-synonymous in the last exon of APOL1. The derived allele of
rs71785313 called APOL1 G2 APOL1 is a 6 base pair deletion, removing amino acids N388 and
Y389. Wild type APOL1 is known as G0. APOL1 alleles G1 and G2 are independent [28]. The
distribution of APOL1 G1 and APOL1 G2 in the present study were significantly different in
latent infections compared to both cases and controls (Tables 3 and 4). The APOL1 G2 allele
carriers had a higher risk of developing HAT after infection by T. b. gambiense than the
APOL1 G0 individuals (p = 0.0011, OR = 2.70, CI95 = [1.49–4.91], BONF = 0.0301). Subjects
Table 2. Association analysis between HAT cases and controls.
CHR Genes SNP BP A1 A2 P BONF FDR_BH FRD_BY OR CI95 HWE FST
4 IL8 rs114259658 74605639 A T 0.7973 1 0.9408 1 1.08 0.59–2.00 0.4410 -0.00361
4 IL8 rs2227307 74606669 T G 0.2343 1 0.5468 1 0.81 0.57–1.15 0.1314 0.00104
4 IL8 rs2227545 74608727 C A 0.1212 1 0.4848 1 1.63 0.88–3.01 1 0.00288
4 IL8 rs58478511 74610033 A G 0.4888 1 0.8235 1 1.14 0.78–1.66 0.8098 -0.00218
5 IL4 rs2243261 132012806 T G 0.1736 1 0.4860 1 0.75 0.49–1.14 0.4260 0.00326
5 IL4 rs2243283 132016593 G C 0.5212 1 0.8235 1 0.87 0.56–1.34 0.2041 -0.00405
5 IL4 rs9282745 132014000 A T 0.9918 1 0.9918 1 1.00 0.57–1.74 0.0706 -0.00265
6 HLAG rs1610696 29798803 G C 0.9145 1 0.9849 1 0.98 0.67–1.44 0.0016 -0.00398
6 HLAG rs2517898 29799746 G C 0.6884 1 0.9178 1 0.93 0.64–1.34 0.1739 -0.00054
6 TNFA rs1800629 31543031 A G 0.8156 1 0.9408 1 1.06 0.66–1.71 0.2207 -0.00108
6 TNFA rs1800630 31542476 A C 0.2117 1 0.5388 1 1.47 0.80–2.67 1 -0.00044
7 IL6 rs1474347 22768124 C A 0.0941 1 0.4393 1 1.91 0.90–4.08 1 0.00671
7 IL6 rs1548216 22769773 C G 0.2988 1 0.6025 1 1.28 0.81–2.02 1 0.00392
7 IL6 rs1818879 22772727 A G 0.1698 1 0.4860 1 0.71 0.43–1.16 0.4504 0.00487
7 IL6 rs2066992 22768249 T G 0.5336 1 0.8235 1 0.82 0.45–1.52 1 -0.00152
7 IL6 rs2069837 22768027 G A 0.0871 1 0.4393 1 0.64 0.38–1.07 0.1147 0.00977
7 IL6 rs2069855 22772624 C T 0.3012 1 0.6025 1 1.41 0.74–2.70 1 -0.00041
12 IFNG rs2069705 68555011 A G 0.9559 1 0.9913 1 1.01 0.72–1.41 0.3431 -0.00206
12 IFNG rs2069722 68548953 A G 0.5588 1 0.8235 1 1.25 0.59–2.62 1 -0.00184
12 IFNG rs2069728 68547784 T C 0.8400 1 0.9408 1 1.04 0.71–1.51 0.3854 -0.00327
12 IFNG rs2430561 68552522 A T 0.1464 1 0.4860 1 1.56 0.86–2.86 0.5307 0.00438
12 IFNG rs78554979 68554636 C T 0.0449* 1 0.4393 1 0.55 0.31–0.99 0.2102 0.00940
16 HP rs8062041 72088964 T C 0.6853 1 0.9178 1 1.07 0.76–1.51 0.6999 -0.00300
22 APOL1 rs71785313 36661916 DEL INSERT 0.5324 1 0.8235 1 1.15 0.74–1.79 0.3534 -0.00147
22 APOL1 rs73885319 36661906 G A 0.7318 1 0.9314 1 0.92 0.59–1.45 1 -0.00325
22 MIF rs12483859 24234807 C T 0.0807 1 0.4393 1 1.38 0.96–1.98 0.1429 0.00610
22 MIF rs34383331 24238079 A T 0.0914 1 0.4393 1 0.67 0.42–1.07 1 0.00581
22 MIF rs36086171 24235455 G A 0.0239* 0.6697 0.4393 1 1.65 1.07–2.53 0.3772 0.02344
CHR: Chromosome number, SNP: single nucleotide polymorphism, BP: Physical position (base-pair in GRCh37), A1: Minor allele name, A2: Major allele
name, P: Exact p-value, BONF: Bonferroni corrected p-value, FDR: false discovery rate, OR: Estimated odds ratio (for A1), CI95: 95% confidence interval,
HWE: Hardy-Weinberg Equilibrium p-value
* P-value significant; DEL: deletion of 6 base pair; INSER: insertion of 6 base pair.
https://doi.org/10.1371/journal.pntd.0005833.t002
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carrying the APOL1 G1 (p = 0.0005, OR = 0.45, CI95 = [0.29–0.70], BONF = 0.0129) had an
increased risk of developing a latent infection but reduced risk of progressing from latent
infection to active HAT than APOL1 G0 (Table 3).
An association was observed at IL6 rs1818879 (Fig 1), indicating that subjects with latent
infections carrying the A allele had a lower risk of progressing to active HAT (p = 0.0001,
OR = 0.39, CI95 = [0.24–0.63], BONF = 0.0034) (Table 3).
The distribution of the MIF rs36086171 G allele differed between cases and controls
(BONF = 0.6697, p = 0.0239, OR = 1.65, CI95 = [1.07–2.53]), and MIF rs12483859 C allele
between latent infections and Controls (BONF = 0.2157, p = 0.0077, OR = 1.86, CI95 = [1.18–
2.95]) but these did not remain significant after Bonferroni correction (Tables 2 and 4).
Table 3. Association analysis between HAT cases and latent infection groups.
CHR Genes SNP BP A1 A2 P BONF FDR_BH FRD_BY OR CI95 HWE FST
4 IL8 rs114259658 74605639 A T 0.7133 1 0.8628 1 0.89 0.47–1.68 0.4410 -0.00384
4 IL8 rs2227307 74606669 T G 0.4650 1 0.7931 1 1.15 0.79–1.66 0.1314 -0.00118
4 IL8 rs2227545 74608727 C A 0.5518 1 0.7931 1 1.20 0.65–2.22 1 -0.00332
4 IL8 rs58478511 74610033 A G 0.4429 1 0.7931 1 0.86 0.59–1.26 0.8098 0.00058
5 IL4 rs2243261 132012806 T G 0.9303 1 0.9306 1 0.98 0.62–1.55 0.4260 -0.00450
5 IL4 rs2243283 132016593 G C 0.5761 1 0.7931 1 0.88 0.55–1.39 0.2041 -0.00504
5 IL4 rs9282745 132014000 A T 0.5372 1 0.7931 1 1.24 0.63–2.46 0.0706 -0.00376
6 HLAG rs1610696 29798803 G C 0.7436 1 0.8628 1 1.08 0.69–1.69 0.0016 -0.00462
6 HLAG rs2517898 29799746 G C 0.5946 1 0.7931 1 1.12 0.75–1.66 0.1739 -0.00272
6 TNFA rs1800629 31543031 A G 0.9306 1 0.9306 1 1.02 0.61–1.72 0.2207 -0.00388
6 TNFA rs1800630 31542476 A C 0.5948 1 0.7931 1 1.19 0.63–2.23 1 -0.00240
7 IL6 rs1474347 22768124 C A 0.7960 1 0.8628 1 1.10 0.54–2.21 1 -0.00380
7 IL6 rs1548216 22769773 C G 0.5169 1 0.7931 1 1.17 0.72–1.90 1 -0.00117
7 IL6 rs1818879 22772727 A G 0.0001* 0.0034** 0.004 0.0133 0.39 0.24–0.63 0.4504 0.08256
7 IL6 rs2066992 22768249 T G 0.1921 1 0.6455 1 0.66 0.36–1.23 1 0.00583
7 IL6 rs2069837 22768027 G A 0.8012 1 0.8628 1 1.08 0.60–1.93 0.1147 -0.00391
7 IL6 rs2069855 22772624 C T 0.3414 1 0.7931 1 1.41 0.70–2.85 1 -0.00194
12 IFNG rs2069705 68555011 A G 0.4609 1 0.7931 1 0.87 0.61–1.25 0.3431 -0.00382
12 IFNG rs2069722 68548953 A G 0.2072 1 0.6455 1 1.80 0.72–4.50 1 0.00331
12 IFNG rs2069728 68547784 T C 0.7288 1 0.8628 1 1.07 0.72–1.60 0.3854 -0.00384
12 IFNG rs2430561 68552522 A T 0.4592 1 0.7931 1 0.81 0.47–1.41 0.5307 -0.00261
12 IFNG rs78554979 68554636 C T 0.0762 1 0.4264 1 0.57 0.31–1.06 0.2102 0.00916
16 HP rs8062041 72088964 T C 0.3551 1 0.7931 1 1.19 0.82–1.73 0.6999 -0.00340
22 APOL1 rs71785313 36661916 DEL INSERT 0.0011* 0.0301** 0.0100 0.0394 2.70 1.49–4.91 0.3534 0.04098
22 APOL1 rs73885319 36661906 G A 0.0005* 0.0129** 0.0065 0.0254 0.45 0.29–0.70 1 0.05137
22 MIF rs12483859 24234807 C T 0.1643 1 0.6455 1 0.77 0.54–1.11 0.1429 0.00376
22 MIF rs34383331 24238079 A T 0.0673 1 0.4264 1 0.64 0.40–1.03 1 0.00985
22 MIF rs36086171 24235455 G A 0.2075 1 0.6455 1 1.32 0.86–2.02 0.3772 0.00459
CHR: Chromosome number, SNP: single nucleotide polymorphism, BP: Physical position (base-pair in GRCh37), A1: Minor allele name, A2: Major allele
name, P: Exact p-value, BONF: Bonferroni corrected p-value, FDR: false discovery rate, OR: Estimated odds ratio (for A1), CI95: 95% confidence interval,
HWE: Hardy-Weinberg Equilibrium p-value
* P-value significant
** Bonferroni correction significant
DEL: deletion of 6 base pair
INSER: insertion of 6 base pair.
https://doi.org/10.1371/journal.pntd.0005833.t003
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No statistically significant differences were observed in allele frequency for the polymor-
phisms of other genes (IL4, IL8, HLA-G, TNFA, HP, IFNG and MIF) between cases and con-
trols; cases and latent infection or latent infection and controls in all the analyses.
Discussion
Association analysis’s undertaken in this study allow us to investigate genetic associations of
candidate genes polymorphisms with HAT in a Guinean population.
The main findings of our study are that the A allele of IL6 rs1818879 and the G allele of
APOL1 G1 appear to be associated with a higher risk of developing a latent infection but a
lower risk of progressing from latent infection with undetectable parasitaemia to active disease.
These alleles thus seem to provide some degree of protection for individuals with latent
Table 4. Association analysis between latent infection and controls groups.
CHR Genes SNP BP A1 A2 P BONF FDR_BH FRD_BY OR CI95 HWE FST
4 IL8 rs114259658 74605639 A T 0.6168 1 0.9090 1 1.22 0.57–2.62 0.4410 -0.00351
4 IL8 rs2227307 74606669 T G 0.0728 1 0.3402 1 0.67 0.43–1.04 0.1314 0.01008
4 IL8 rs2227545 74608727 C A 0.4602 1 0.8088 1 1.31 0.64–2.69 1 -0.00240
4 IL8 rs58478511 74610033 A G 0.1492 1 0.5455 1 1.39 0.89–2.17 0.8098 0.00690
5 IL4 rs2243261 132012806 T G 0.2078 1 0.5818 1 0.71 0.42–1.21 0.4260 -0.00060
5 IL4 rs2243283 132016593 G C 0.9907 1 0.9907 1 1.00 0.59–1.70 0.2041 -0.00552
5 IL4 rs9282745 132014000 A T 0.4863 1 0.8088 1 0.77 0.38–1.59 0.0706 -0.00246
6 HLAG rs1610696 29798803 G C 0.6677 1 0.9337 1 0.90 0.56–1.45 0.0016 -0.00503
6 HLAG rs2517898 29799746 G C 0.2517 1 0.6407 1 0.76 0.48–1.21 0.1739 0.00193
6 TNFA rs1800629 31543031 A G 0.8195 1 0.9337 1 1.07 0.61–1.87 0.2207 -0.00452
6 TNFA rs1800630 31542476 A C 0.8519 1 0.9337 1 1.07 0.53–2.17 1 -0.00547
7 IL6 rs1474347 22768124 C A 0.1617 1 0.5455 1 1.87 0.78–4.50 1 0.00398
7 IL6 rs1548216 22769773 C G 0.8231 1 0.9337 1 1.07 0.61–1.86 1 -0.00433
7 IL6 rs1818879 22772727 A G 0.0091* 0.2542 0.0636 0.2496 2.06 1.20–3.56 0.4504 0.02987
7 IL6 rs2066992 22768249 T G 0.3577 1 0.8088 1 1.39 0.69–2.78 1 -0.00258
7 IL6 rs2069837 22768027 G A 0.1754 1 0.5455 1 0.65 0.35–1.21 0.1147 0.00748
7 IL6 rs2069855 22772624 C T 0.8764 1 0.9337 1 1.07 0.46–2.51 1 -0.00504
12 IFNG rs2069705 68555011 A G 0.3858 1 0.8088 1 1.21 0.78–1.88 0.3431 -0.00064
12 IFNG rs2069722 68548953 A G 0.4910 1 0.8088 1 0.69 0.24–1.97 1 -0.00276
12 IFNG rs2069728 68547784 T C 0.7634 1 0.9337 1 0.93 0.58–1.49 0.3854 -0.00473
12 IFNG rs2430561 68552522 A T 0.0729 1 0.3402 1 1.89 0.94–3.80 0.5307 0.01195
12 IFNG rs78554979 68554636 C T 0.9004 1 0.9337 1 0.96 0.49–1.89 0.2102 -0.00468
16 HP rs8062041 72088964 T C 0.5508 1 0.8569 1 0.88 0.58–1.33 0.6999 -0.00241
22 APOL1 rs71785313 36661916 DEL INSERT 0.0070* 0.1973 0.0636 0.2496 0.39 0.20–0.78 0.3534 0.02888
22 APOL1 rs73885319 36661906 G A 0.0056* 0.1570 0.0636 0.2496 2.09 1.24–3.53 1 0.03883
22 MIF rs12483859 24234807 C T 0.0077* 0.2157 0.0636 0.2496 1.86 1.18–2.95 0.1429 0.03028
22 MIF rs34383331 24238079 A T 0.8246 1 0.9337 1 1.06 0.62–1.81 1 -0.00513
22 MIF rs36086171 24235455 G A 0.4467 1 0.8088 1 1.24 0.72–2.13 0.3772 -0.00240
CHR: Chromosome number, SNP: single nucleotide polymorphism, BP: Physical position (base-pair in GRCh37), A1: Minor allele name, A2: Major allele
name, P: Exact p-value, BONF: Bonferroni corrected p-value, FDR: false discovery rate, OR: Estimated odds ratio (for A1), CI95: 95% confidence interval,
HWE: Hardy-Weinberg Equilibrium p-value
* P-value significant
DEL: deletion of 6 base pair
INSER: insertion of 6 base pair.
https://doi.org/10.1371/journal.pntd.0005833.t004
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infections, providing the ability to maintain infection levels that are undetectable by micros-
copy. However, the APOL1 G2 allele increased the risk of progressing from latent infection to
active HAT. The associations with the APOL1 G1 and G2 polymorphisms confirm our previ-
ous observations of these SNPs with a more limited sample [20], they were genotyped again in
this study as part of the larger multi-country TrypanoGEN consortium study, on an extensive
sample from Guinea. Cooper et al. found an association between G2 and HAT and Controls in
T. b. rhodesiense in Uganda [20].
APOL1 is a component of the trypanosome lytic factor (TLF) of human serum that confers
resistance to T. b. brucei [29,30]. APOL1forms pores in the parasite endolysosomal membranes
and triggers lysosome swelling which leads to trypanolysis [31]. APOL1 expression is also
induced by T. b. gambiense infection enhancing its lytic activity [32]. African trypanosomes,
except T. b. gambiense and T. b. rhodesiense are lysed by APOL1. These two subspecies can
resist lysis by APOL1 because they express the serum resistance glycoprotein (TgsGP) and
serum resistance-associated protein (SRA), respectively [33–35]. T. b. rhodesiense SRA inhibits
APOL1 by direct binding but TgsGP acts by limiting uptake of APOL1. T. b. gambiense (group
1) also can resist TLF-1 killing because coding sequence mutations to the TbgHpHbR, reduce
expression of Hp/Hb receptor and limit TLF-1 uptake [36]. The mode of action of G1 is
unknown but the G2 mutation limits binding of SRA to APOL1 and should therefore make
APOL1 G2 lytic to T. b. rhodesiense but this mechanism could not effect T. b. gambiense, which
does not have the SRA gene [28,37]. In this study, we found that the 6 base pair deletion in
APOL1 G2 is risk factor for developing an active T. b. gambiense infection from a latent
infection.
IL6 rs1818879 A allele carriers had a lower risk of developing the disease. rs1818879 appears
to fall within a CCCTC-Binding factor (CTCF) binding site and GTEx reports rs1818879 as an
eQTL for AC073072, a novel antisense RNA gene within IL6 on the opposite strand about
which little is known [38]. CTCF is a zinc finger protein that can be involved in activation or
repression of gene expression and the disruption of this binding site may account for the
eQTL associated with AC073072 [39]. Although the mechanism remains unclear, these data
suggest that rs1818879 may be a functional polymorphism and not just a marker for differ-
ences in response to infection.
It has been shown that IL6 could play a role on the modification of blood brain barrier per-
meability in vitro together with other pro-inflammatory cytokines such as IL1 and TNFA in
blood and/or in CNS [40]. IL6 plasma levels were found to be significantly higher in individu-
als with latent infection from Guinea as compared to controls or HAT patients [17]. Girard
and al. (2005) showed that IL6 synthesis was induced in bone marrow by T. b. gambiense in
vitro [41]. Therefore, Il6 appears as an important inflammatory cytokine mediating T. b. gam-
biense response and suggest that IL6 could play a role in the phenomenon of latent infections
without parasitological confirmation. The result obtained with IL6 rs1818879 in our study is
consistent with the data from a candidate gene association study in DRC, where rs2069849 in
IL6 was shown to be associated with a decreased risk of developing the disease [16].
Fig 1. Schematic of single nucleotide polymorphisms of Interleukin-6 selected from 2,000bp up and downstream (5’ and 3’) of the transcript
region.
https://doi.org/10.1371/journal.pntd.0005833.g001
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Our data show that the frequency of the G minor allele of MIF rs36086171 was higher in
cases than in controls (uncorrected p = 0.0239, OR = 1.65, CI95 = [1.07–2.53]) and MIF
rs12483859 C allele in latent infections than in controls (uncorrected p = 0.0077, OR = 1.86,
CI95 = [1.18–2.95]). MIF is an important component of the host response implicated in the
antimicrobial response and promotes the secretion and activation of pro-inflammatory cyto-
kines, by immune cells [42,43]. Low expression of MIF has been described as favoring infec-
tion and disease progression in leishmaniasis [44]. We did not find a significant difference
after correction (BONF = 0.0588), but it is known that this gene can contribute to disease
development in a mice experimental model [45].
In conclusion, this study provides further evidence that the clinical diversity of sleeping sick-
ness is partly due to the genetic diversity of the hosts. Our data demonstrate that the outcome of
the disease is affected by three polymorphisms (APOL1 G1, G2 and IL6 rs1818879) in the Guin-
ean population. This study was performed in the framework of the TrypanoGEN consortium to
systematically investigate the role of host genetics in disease susceptibility and progression
across East and West African populations. Further studies need to be conducted to confirm
these results and to determine the mechanisms by which these alleles affect disease progression
and outcome in HAT and could lead to the discovery of human natural resistance mechanisms
and thus to the development of new tools for the control of this neglected tropical disease.
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